A clinical trial can be sponsored by an industry (company) or non-industry (government, individual/investigator-initiated, or institution).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Figure one: Non-industry-sponsored clinical trials by year. Credit: GlobalData.

When looking at non-industry-sponsored clinical trials since 2017, there has been a steady increase, from 32.1% of all clinical trials that year to 34.5% in 2019. This can be seen in figure one.

An analysis can be completed for those non-industry-sponsored clinical trials in 2019 by using the clinical trials database of GlobalData’s Pharma Intelligence Centre. In this article, a small number of phase zero, phase one / two, phase two / three and phase three / four trials were combined with phase one, phase two, phase three and phase four trials, respectively.

Figure two: 2019 non-industry-sponsored clinical trials by phase. Credit: GlobalData.

When looking at non-industry-sponsored clinical trials in 2019 in the database, it can be seen that phase two clinical trials outnumbered all other phases. Phase two clinical trials made up 49.7% of all clinical trials in 2019, with phase four following with 19.4%, phase one next with 16.4% and phase three with 14.5%. This can be seen in figure two.

Figure three: 2019 non-industry-sponsored clinical trials by therapy area. Credit: GlobalData.

Lastly, oncology was the top therapy area for non-industry sponsored clinical trials in 2019, as can be seen in figure three. They made up 25.7% of all clinical trials. The central nervous system (CNS) was second with 23.5%, followed by cardiovascular (8.9%), infectious disease (8.5%) and metabolic disorders (7.4%). Oncology, CNS, cardiovascular and infectious disease clinical trials all showed an increase in 2019 from 2018.